TipRanks
pc:sol21

Solstice Oncology

A clinical-stage immuno-oncology company focused on treating cancer earlier in the neoadjuvant setting. The company is advancing porustobart, an Fc-enhanced CTLA-4 antibody, across clinical indications including stage II-III colon cancer.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$225M
Total Amount Raised$225M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$225M
Latest Funding Amount$225M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 09, 2026
Series A
$225.00M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to Solstice Oncology, helping you discover and navigate related company profiles.

Related News and Analysis